Scholarlink

Purpose of the Review <p>The purpose of this review is to provide details of the STOP Gout trial, among the first randomized, blinded studies to compare allopurinol with febuxostat using a treat-to-target strategy. In addition to details of its design and trial results, this review summarizes findings from pre-planned and other analyses, as well as an associated biorepository that has enabled the identification of biomarkers impacted by highly effective urate-lowering therapy (ULT).</p> Recent Findings <p>In addition to primary trial findings demonstrating the non-inferiority of allopurinol to febuxostat in flare prevention and the achievement of serum urate goals, data generated from the STOP Gout trial have provided additional insights that have included: 1) the relative efficacy and safety of both allopurinol and febuxostat in participants with stage 3 chronic kidney disease; 2) patient factors associated with the achievement of serum urate goals; 3) the frequency and determinants of mobilization flares during the early phases of treat-to-target treatment; 4) the heightened risk of flare following discontinuation of anti-inflammatory prophylaxis; 5) limited persistence of ULT following transitions back to real-world care; 6) rapid gains in health-related quality of life accompanying highly effective ULT that pre-date reductions in flare risk; and 7) the positive effects of urate-lowering on measures of systemic inflammation and other circulating biomarkers.</p> Summary <p>In addition to informing the comparative efficacy and safety of allopurinol and febuxostat, STOP Gout and the resources generated from this trial have enabled research that has further informed our understanding of gout and its management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treat-to-Target Urate-lowering Therapy: Lessons Learned from the STOP Gout Study

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Ted R. Mikuls,
  • Lindsay Helget,
  • Jeff Newcomb,
  • Austin Wheeler,
  • James R. O’Dell

摘要

Purpose of the Review

The purpose of this review is to provide details of the STOP Gout trial, among the first randomized, blinded studies to compare allopurinol with febuxostat using a treat-to-target strategy. In addition to details of its design and trial results, this review summarizes findings from pre-planned and other analyses, as well as an associated biorepository that has enabled the identification of biomarkers impacted by highly effective urate-lowering therapy (ULT).

Recent Findings

In addition to primary trial findings demonstrating the non-inferiority of allopurinol to febuxostat in flare prevention and the achievement of serum urate goals, data generated from the STOP Gout trial have provided additional insights that have included: 1) the relative efficacy and safety of both allopurinol and febuxostat in participants with stage 3 chronic kidney disease; 2) patient factors associated with the achievement of serum urate goals; 3) the frequency and determinants of mobilization flares during the early phases of treat-to-target treatment; 4) the heightened risk of flare following discontinuation of anti-inflammatory prophylaxis; 5) limited persistence of ULT following transitions back to real-world care; 6) rapid gains in health-related quality of life accompanying highly effective ULT that pre-date reductions in flare risk; and 7) the positive effects of urate-lowering on measures of systemic inflammation and other circulating biomarkers.

Summary

In addition to informing the comparative efficacy and safety of allopurinol and febuxostat, STOP Gout and the resources generated from this trial have enabled research that has further informed our understanding of gout and its management.